Anti-Fas antibody

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Fas antibody (AB110021)

ab110021, staining CD95 in Human tonsil tissue by immunohistochemistry.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Fas antibody (AB110021)

ab110021, staining CD95 in Human small intestine tissue by immunohistochemistry.

• WB

Unknown

Western blot - Anti-Fas antibody (AB110021)

Primary incubation was 1 hour. Detected by chemiluminescence.

All lanes:

Western blot - Anti-Fas antibody (ab110021) at 0.1 µg/mL

All lanes:

MOLT4 cell lysate (in RIPA buffer) at 35 µg

Predicted band size: 37 kDa

false

• WB

CiteAb

Western blot - Anti-Fas antibody (AB110021)

Fas western blot using anti-Fas antibody ab110021. Publication image and figure legend from Huang, W., Bei, L., et al., 2018, Oncotarget, PubMed 29899829.

ab110021 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab110021 please see the product overview.

Fap1-inhibition increased Fas or oxaliplatin induced apoptosis in CD133+ colon cancer cells(A) Fap1-blocking SLV peptide increases Fas-induced apoptosis. Total SW480 or SW620 cells were treated with SLV peptide (or VLS control), with or without Fas-agonist antibody, and analyzed for apoptosis by Annexin V staining. Significant differences indicated by *, **, or *** (p<0.01, n=4 for all comparisons). (B) Fap1-inhibition increases Fas or oxaliplatin induced apoptosis in CD133+ SW620 cells. CD133+ SW620 cells were analyzed for apoptosis by Annexin V staining, with or without Fas-agonist antibody. Some cells were treated with SLV peptide (or VLS control) or transduced with a vector to express Fap1 specific shRNAs (or scrambled control). Significant differences indicated by *, **, ***, or # (p<0.001, n=4 for all comparisons). (C) Fap1-inhibition increases Fas induced caspase 8 cleavage in CD133+ SW620 cells. Cells were analyzed by ELISA for cleavage of caspase 8 (death receptor induced apoptosis). Statistically significant differences indicated by * or ** (p<0.001, n=4). (D) Oxaliplatin treatment increases caspase 9 cleavage in CD133+ SW620 cells. Cells were analyzed by ELISA for cleavage of caspase 9 (intrinsic apoptosis). Statistically significant differences indicated by *, **, ***, or # (p<0.001, n=4). (E) Plasma membrane expression of Fas was not altered by SLV peptide or oxaliplatin treatment of CD133+ SW620 cells. Western blots of cell lysates were probed for Fas or Na+/K+ ATPase (as a loading control). (F) Fap1 inhibition increases Fas or oxaliplatin induced apoptosis in CD133+ SW480 cells. Similar experiments were performed with the SW480 cell line. Statistically significant differences are indicated by * or ** (p<0.001, n=6 for both comparisons).

false